Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: Breast cancer facts that could save lives

2.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says

3.

Low Income, Education Tied to Depression in Older Adults

4.

Remote monitoring can improve recovery from cancer surgery

5.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot